A detailed history of Two Sigma Investments, LP transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Two Sigma Investments, LP holds 660,059 shares of ALXO stock, worth $851,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares
660,059
Previous 292,226 125.87%
Holding current value
$851,476
Previous $1.76 Million 31.84%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.81 - $8.13 $665,777 - $2.99 Million
367,833 Added 125.87%
660,059 $1.2 Million
Q2 2024

Aug 14, 2024

BUY
$5.84 - $17.56 $1.32 Million - $3.98 Million
226,771 Added 346.45%
292,226 $1.76 Million
Q1 2024

May 15, 2024

SELL
$10.95 - $16.79 $5,102 - $7,824
-466 Reduced 0.71%
65,455 $729,000
Q4 2023

Feb 14, 2024

BUY
$4.81 - $15.38 $317,080 - $1.01 Million
65,921 New
65,921 $981,000
Q1 2023

May 15, 2023

BUY
$4.52 - $11.71 $281,826 - $730,130
62,351 Added 135.55%
108,351 $489,000
Q4 2022

Feb 14, 2023

SELL
$9.51 - $12.95 $576,800 - $785,443
-60,652 Reduced 56.87%
46,000 $518,000
Q3 2022

Nov 14, 2022

SELL
$8.23 - $15.14 $1.13 Million - $2.09 Million
-137,820 Reduced 56.37%
106,652 $1.02 Million
Q2 2022

Aug 15, 2022

BUY
$5.89 - $19.46 $573,550 - $1.89 Million
97,377 Added 66.2%
244,472 $1.98 Million
Q1 2022

May 16, 2022

SELL
$13.65 - $22.06 $3.3 Million - $5.34 Million
-242,107 Reduced 62.21%
147,095 $2.49 Million
Q4 2021

Feb 14, 2022

BUY
$21.49 - $74.4 $8.3 Million - $28.7 Million
386,302 Added 13320.76%
389,202 $8.36 Million
Q3 2021

Nov 15, 2021

BUY
$52.51 - $80.91 $152,279 - $234,639
2,900 New
2,900 $214,000

Others Institutions Holding ALXO

About ALX ONCOLOGY HOLDINGS INC


  • Ticker ALXO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,747,100
  • Market Cap $52.6M
  • Description
  • ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...
More about ALXO
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.